Kezar Life Sciences, Inc. (KZR) Operating Income (Loss) USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Kezar Life Sciences, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2024.
  • Kezar Life Sciences, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$23.7 M, a 3.32% increase year-over-year.
  • Kezar Life Sciences, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$111 M, a 38.6% decline year-over-year.
  • Kezar Life Sciences, Inc. annual Operating Income (Loss) for 2023 was -$111 M, a 56.6% decline from 2022.
  • Kezar Life Sciences, Inc. annual Operating Income (Loss) for 2022 was -$71.2 M, a 30.2% decline from 2021.
  • Kezar Life Sciences, Inc. annual Operating Income (Loss) for 2021 was -$54.7 M, a 27.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$111 M -$23.7 M +$813 K +3.32% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$111 M -$34.6 M -$14.6 M -72.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 -$96.9 M -$25.5 M -$6.6 M -34.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$90.3 M -$26.8 M -$10.5 M -64.1% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$79.8 M -$24.5 M -$8.65 M -54.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$71.2 M -$20 M -$5.93 M -42.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$65.2 M -$18.9 M -$4.43 M -30.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$60.8 M -$16.3 M -$3.31 M -25.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$57.5 M -$15.9 M -$2.83 M -21.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$54.7 M -$14.1 M -$3.04 M -27.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 -$51.6 M -$14.5 M -$2.95 M -25.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$48.7 M -$13 M -$3.16 M -32% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$45.5 M -$13 M -$2.57 M -24.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$43 M -$11.1 M -$1.07 M -10.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-14
Q3 2020 -$41.9 M -$11.6 M -$1.87 M -19.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$40 M -$9.85 M -$498 K -5.32% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$39.5 M -$10.5 M -$2.17 M -26.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 -$37.3 M -$10 M -$3.57 M -55.6% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-17
Q3 2019 -$33.8 M -$9.68 M -$3.42 M -54.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$30.4 M -$9.36 M -$2.41 M -34.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$27.9 M -$8.31 M -$3.22 M -63.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$24.7 M -$6.43 M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-11
Q3 2018 -$6.26 M -$4.07 M -186% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$6.95 M -$5.07 M -269% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$5.09 M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q3 2017 -$2.19 M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$1.88 M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.